Earnings Insights · MRK · Q3 FY2026

Merck Q3 2026 Earnings: Sales Growth Holds, but Purchase Timing and Higher Investment Pressure EPS

By AlgovestIQ ResearchPublished

Share

Read Merck & Co.’s results announcement (Form 8-K, filed Oct 29, 2026)

Key earnings findings

Merck (MRK) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Merck reported Q3 FY2026 revenue of $18.09B against the $17.33B analyst estimate, a 4.4% beat, and EPS of $2.49 against the $2.09 analyst estimate, a 19.1% beat.
  2. Management expects foreign exchange to contribute roughly 1 percentage point to full-year sales growth and approximately $0.15 per share to non-GAAP EPS, based on mid-October exchange rates.
  3. MRK closed at $146.33 on Oct 29, 2026, up 3.8% from $140.93 on Oct 28, 2026, the last close before the results were released.

Sources: Merck & Co. results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Merck beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$18.09B
$17.33B
+4.4%
EPS
$2.49
$2.09
+19.1%
  • EPS has beaten the estimate in 7 of the most recent reported quarters.
  • Revenue surprise across the last 8 reported quarters has ranged from -0.4% to 4.4%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Merck reported third-quarter sales of $18.1B, up 5% year over year, supported by continued oncology growth, rapid WINREVAIR adoption and contributions from newer products. GAAP EPS fell 12% to $2.04 and non-GAAP EPS declined 3% to $2.49 as higher launch spending, pipeline investment, intangible amortization and interest expense outweighed revenue growth.

The quarter reinforced that Merck’s emerging products are beginning to diversify growth beyond KEYTRUDA. However, approximately $550M of third-quarter sales benefited from favorable purchase timing, while management also signaled moderating KEYTRUDA growth in 2027 and higher operating expenses as it invests behind its pipeline and launches.

Earnings Snapshot

MetricReportedChange
Total sales$18.1B+5% (+4% ex-FX)
Pharmaceutical sales$16.3B+4%
Animal Health sales$1.7B+4%
GAAP net income$5.1B-12%
GAAP EPS$2.04-12%
Non-GAAP net income$6.2B-4%
Non-GAAP EPS$2.49-3%
GAAP gross margin72.9%Down from 77.7%
Non-GAAP gross margin81.4%Down from 81.9%
KEYTRUDA/KEYTRUDA QLEX sales$8.6B+6%
WINREVAIR sales$694M+93%
GARDASIL/GARDASIL 9 sales$2.0B+14%
WELIREG sales$307M+56%
Animal Health sales$1.7B+4%

The Bigger Story

Merck’s central strategic challenge remains preparing for the eventual loss of exclusivity for KEYTRUDA while building enough new revenue sources to limit the earnings disruption. The third quarter showed progress on that transition: WINREVAIR nearly doubled sales, WELIREG grew 56%, and newer products including ENFLONSIA and OHTUVAYRE added to growth.

Yet KEYTRUDA remains the company’s largest earnings driver by a wide margin, accounting for $8.6B of quarterly sales, or nearly half of total revenue. Management expects KEYTRUDA to remain an important contributor in 2027, but said growth should moderate as penetration approaches peak levels in certain approved indications and as pricing pressure develops in markets outside the U.S., particularly Germany.

The pipeline is also becoming more consequential to the investment case. Merck highlighted positive late-stage data for sacituzumab tirumotecan, or sac-TMT, in endometrial cancer and for intismeran autogene plus KEYTRUDA in resected melanoma. These programs could support the company’s longer-term oncology strategy, but their commercial value remains dependent on regulatory outcomes, further trial readouts and successful launches.

Revenue and Operating Performance

Pharmaceutical sales increased 4% to $16.3B. Growth came primarily from oncology, vaccines, WINREVAIR and recently launched products, partly offset by expected declines in mature products facing generic competition.

The KEYTRUDA franchise, including subcutaneous KEYTRUDA QLEX, grew 6% to $8.6B. Management cited greater use in earlier-stage cancers, including triple-negative breast, cervical, head and neck, and bladder cancers, along with continued demand in metastatic indications such as urothelial cancer. KEYTRUDA QLEX contributed $830M in sales, reflecting ongoing adoption of the subcutaneous formulation.

The reported KEYTRUDA growth rate was affected by purchase timing. Management said U.S. wholesaler purchasing was unfavorable compared with the prior year, though this was largely offset by higher channel inventory. The company expects the related inventory benefit to unwind in the fourth quarter.

WINREVAIR generated $694M in sales, up 93% year over year, as demand expanded in pulmonary arterial hypertension and international launches progressed. Sales also benefited from wholesaler and specialty-pharmacy purchasing patterns. Management quantified a $50M third-quarter timing benefit for WINREVAIR and expects it to reverse in the fourth quarter.

GARDASIL and GARDASIL 9 sales increased 14% to $2.0B, driven by U.S. public-sector purchasing patterns and higher net pricing. Management said a significant U.S. Centers for Disease Control and Prevention purchase contributed to results. Of the company’s total $550M purchase-timing benefit in the quarter, $300M related primarily to vaccines, especially GARDASIL. Merck expects $50M of that amount to unwind in the fourth quarter and the remaining $250M in 2027.

Several newer products were meaningful contributors, although their revenue bases remain smaller than KEYTRUDA’s:

  • WELIREG sales rose 56% to $307M, helped by U.S. demand and international launch uptake.
  • ENFLONSIA sales reached $187M, up 138%, driven by seasonal demand and inventory building.
  • OHTUVAYRE produced $184M in sales following Merck’s October 2025 acquisition of Verona Pharma.
  • PREVYMIS sales grew 30% to $347M.
  • CAPVAXIVE sales rose 8% to $263M, as international launches partly offset lower U.S. adult pneumococcal vaccination rates and lower net pricing.

Merck’s mature-product erosion remained significant. BRIDION sales fell 67% to $144M after U.S. loss of exclusivity, while JANUVIA/JANUMET sales declined 39% to $380M amid generic competition. LAGEVRIO revenue fell 88% to $17M on lower demand in Japan.

Animal Health revenue increased 4% to $1.7B, with Companion Animal sales up 6% on new launches and Livestock sales up 2% on poultry demand. The segment provided steady diversification, although it remains a relatively small contributor compared with human pharmaceuticals.

Profitability and Margins

Revenue growth did not translate into earnings growth. GAAP EPS declined to $2.04 from $2.32, while non-GAAP EPS declined to $2.49 from $2.58.

GAAP gross margin fell 480 basis points to 72.9%, primarily due to higher intangible-asset amortization, restructuring charges and production costs. On a non-GAAP basis, gross margin declined 50 basis points to 81.4%, with higher production costs cited as the main factor.

Non-GAAP operating expenses increased 12% to $7.4B. Merck is spending more to support product launches and advance its pipeline, while also absorbing a $400M upfront charge tied to a global licensing agreement with SciBrunch for an investigational KRAS G12D inhibitor. The company received a partial offset from external funding related to TMT development and from its ongoing optimization program.

Both GAAP and non-GAAP EPS included a $0.12-per-share charge associated with the SciBrunch agreement. The year-earlier quarter included a $0.10-per-share milestone charge tied to MK-2010 technology transfer, making the comparison somewhat less severe than the reported EPS decline alone suggests.

Other expense also increased materially. Non-GAAP other expense was $420M, versus $106M a year earlier, primarily because of higher financing costs related to recent business-development transactions. This is an important earnings headwind as Merck continues to use acquisitions and licensing deals to strengthen its post-KEYTRUDA portfolio.

Demand, Customers and Pricing

Demand trends were broadly constructive across Merck’s principal growth products, but some reported growth was amplified by inventory movements and public-sector purchasing patterns.

For WINREVAIR, management said nearly 1,600 new U.S. patients received prescriptions during the quarter. About 30% had not been on a regimen containing a prostacyclin, suggesting use is extending beyond a narrowly defined treatment population. International launches are also progressing, and an FDA label update incorporated data from the Phase 3 HYPERION study in recently diagnosed pulmonary arterial hypertension.

Management described early prescription activity for LIPFENDRA as encouraging, with more than 11,000 prescriptions from more than 6,500 prescribers during the third quarter. Most prescriptions came from patients already taking other lipid-lowering therapies rather than from switches away from injectable PCSK9 therapies. Merck expects commercial coverage to build through 2027 and Medicare access to develop in 2028, meaning early prescription activity may not translate immediately into material revenue.

Vaccine demand is less certain. CAPVAXIVE’s U.S. sales declined despite market-share gains because adult pneumococcal vaccination rates fell. Management also said it is monitoring broader vaccine hesitancy and reduced utilization, which could constrain growth in the category.

What is Merck’s guidance for full-year 2026?

Merck narrowed and raised the midpoint of its full-year 2026 outlook.

MetricUpdated 2026 OutlookPrior Outlook
Sales$66.8B to $67.3B$66.3B to $67.3B
Non-GAAP gross marginApproximately 81%Approximately 81%
Non-GAAP operating expenses$42.4B to $42.9B$42.0B to $42.7B
Non-GAAP other expense, netApproximately $1.4BApproximately $1.4B
Non-GAAP tax rate32.0% to 33.0%35.0% to 36.0%
Non-GAAP EPS$2.77 to $2.82$2.66 to $2.76
Diluted share countApproximately 2.48BApproximately 2.48B

Management expects foreign exchange to contribute roughly 1 percentage point to full-year sales growth and approximately $0.15 per share to non-GAAP EPS, based on mid-October exchange rates.

The EPS outlook includes one-time charges of $3.62 per share for the Cidara acquisition, $2.31 per share for the Terns acquisition and $0.12 per share for the SciBrunch license agreement. The updated operating-expense range reflects the SciBrunch charge.

For 2027, management expects moderate revenue growth, but identified more than $2B of headwinds from generic competition and loss of exclusivity affecting BRIDION, the JANUVIA franchise and Adempas. Management also expects underlying operating expenses to rise at a mid- to high-single-digit rate as it funds launches and clinical development.

Balance Sheet, Cash Flow and Capital

Merck said its capital-allocation priorities remain investment in internal development, business development and a dividend that it intends to increase over time. Management expects approximately $3B of share repurchases in 2026.

The company also said it retains financial flexibility within its investment-grade credit rating to pursue additional transactions. However, higher interest expense already weighed on third-quarter profitability, illustrating the near-term earnings cost of recent deal activity even as management seeks to expand its long-term portfolio.

What Investors Should Watch

1. KEYTRUDA growth after the fourth-quarter inventory reversal

Merck expects $200M of third-quarter KEYTRUDA purchase-timing benefits to unwind in the fourth quarter. Underlying demand in earlier-stage indications remains important, but investors will need to distinguish reported sales growth from channel inventory effects as the franchise approaches peak penetration in some markets.

2. WINREVAIR’s demand trajectory and revenue quality

WINREVAIR’s 93% sales growth is a major positive, but $50M of third-quarter sales came from favorable purchasing patterns. Sustained patient starts, international uptake and conversion of the expanded label into broader use will matter more than quarterly inventory changes.

3. The pace of new-product diversification

WELIREG, ENFLONSIA, OHTUVAYRE and LIPFENDRA represent pieces of Merck’s post-KEYTRUDA growth strategy. Investors should monitor whether these products can collectively offset accelerating declines in BRIDION, JANUVIA/JANUMET and other mature products.

4. Pipeline execution in oncology

Sac-TMT’s endometrial-cancer application has an FDA action date of June 15, 2027, while Merck and Moderna plan a regulatory filing for intismeran plus KEYTRUDA in melanoma. Positive approvals and additional pivotal data would strengthen the company’s ability to rebuild oncology revenue beyond KEYTRUDA’s exclusivity period. Conversely, Merck’s withdrawal of the I-DXd application in small-cell lung cancer shows that not every late-stage program will advance as planned.

5. Expense growth and financing costs

Management plans to increase underlying operating expenses at a mid- to high-single-digit rate in 2027. The investment may be appropriate if launches and pipeline programs deliver, but it raises the bar for revenue conversion and could limit near-term EPS growth.

AlgovestIQ Takeaway

Merck’s third quarter was operationally solid but financially mixed. Sales growth remained intact, with KEYTRUDA, WINREVAIR, GARDASIL and several newer products offsetting sharp generic-driven declines elsewhere in the portfolio. The company also raised the midpoint of its full-year sales and adjusted EPS guidance.

The quality of that growth deserves scrutiny. Roughly $550M of quarterly sales benefited from purchase timing, with part of the benefit set to reverse in the fourth quarter and another portion, largely related to vaccines, expected to unwind in 2027. That does not negate underlying demand, but it means the reported 5% sales increase overstates the recurring run rate.

Merck is also accepting lower near-term earnings leverage in exchange for heavier launch spending, pipeline investment and business development. Non-GAAP EPS fell despite revenue growth, while higher interest expense became a more visible drag. The key question is whether the company’s spending on acquisitions, licensing and clinical development produces enough commercially meaningful assets before KEYTRUDA faces a more material exclusivity-related decline.

The evidence supporting that transition is improving. WINREVAIR has become a substantial product quickly, KEYTRUDA QLEX is gaining adoption, and the late-stage oncology pipeline has generated notable clinical and regulatory progress. Still, investors should look for cleaner underlying sales growth after inventory effects reverse, continued WINREVAIR execution, and tangible evidence that Merck’s new products and pipeline can narrow the company’s dependence on KEYTRUDA.

How did MRK stock react?

MRK closed at $146.33 on Oct 29, 2026, up 3.8% from $140.93 on Oct 28, 2026, the last close before the results were released.

SessionCloseChange
Oct 28, 2026 (before release)$140.93—
Oct 29, 2026$146.33+3.8%
Oct 30, 2026$149.52+6.1%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Merck & Co. Q3 FY2026 earnings call transcript, as of Oct 29, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Merck & Co. Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 29, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 29, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.